Compare PERF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERF | CRBP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | Taiwan | United States |
| Employees | 353 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1M | 147.4M |
| IPO Year | N/A | 2014 |
| Metric | PERF | CRBP |
|---|---|---|
| Price | $1.71 | $10.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | ★ 297.4K | 193.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $12.93 | N/A |
| Revenue Next Year | $9.44 | $100.00 |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.24 | $5.78 |
| 52 Week High | $2.67 | $20.56 |
| Indicator | PERF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 55.57 |
| Support Level | $1.68 | $9.86 |
| Resistance Level | $1.85 | $10.04 |
| Average True Range (ATR) | 0.06 | 0.75 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 90.32 | 67.69 |
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.